Intrathecal TRH shows limited efficacy reducing infarct volume or inflammation in rabbit cerebral ischemia
Background
Cerebral ischemia, a leading cause of disability and death, triggers complex neuroinflammatory and oxidative stress cascades that exacerbate neuronal damage. Current therapeutic strategies often fall short in fully mitigating these secondary injury mechanisms. Thyrotropin-releasing hormone (TRH), a neuropeptide, has demonstrated neuromodulatory, antioxidant, and anti-inflammatory properties in various central nervous system injury models. However, its specific neuroprotective efficacy against embolic cerebral ischemia, a common stroke subtype, remained largely unexplored, highlighting a critical gap in understanding its potential therapeutic role.
Study Design
Researchers investigated the effects of intrathecal TRH in a rabbit model of embolic cerebral ischemia. Twenty adult female New Zealand white rabbits were divided into two groups (n = 10 per group): a control group and a TRH-treated group. Ischemia was induced by injecting broken autologous blood clots into the right common carotid artery. Forty-five minutes post-embolization, the treatment group received intrathecal TRH (0.20 mg/kg) via the cisterna magna. Primary endpoints included cerebral infarct volume measured by computerized histopathological image analysis, and levels of serum interleukin-1β (IL-1β), CSF lactate, and CSF malondialdehyde (MDA) assessed at baseline and 24 hours after embolization.
Results
At 24 hours post-embolization, mean cerebral infarct volumes were 122.84 ± 15.84 mm³ in the TRH-treated group and 126.79 ± 14.04 mm³ in controls, showing no statistically significant difference (p = 0.496). Serum IL-1β concentrations and CSF levels of lactate and malondialdehyde (MDA) significantly increased in both groups from baseline (p <.05), indicating successful ischemia induction. While the TRH-treated group exhibited numerically decreased levels of CSF lactate, CSF MDA, and serum IL-1β following embolization compared to controls, these reductions were not statistically significant in any group comparison (p >.05).
Key Findings
- Intrathecal TRH (0.20 mg/kg) did not significantly reduce cerebral infarct volume (p = 0.496) in rabbits.
- Mean infarct volumes were 122.84 ± 15.84 mm³ (TRH) vs 126.79 ± 14.04 mm³ (control) at 24 hours.
- Serum
IL-1β, CSF lactate, and CSFMDAlevels increased significantly in both groups (p <.05) post-embolization. - Numerically decreased levels of
IL-1β, CSF lactate, and CSFMDAwere observed in the TRH group, but these were not statistically significant (p >.05).
Why It Matters
This study suggests that at the tested dose and duration, intrathecal TRH may not offer significant neuroprotection against embolic cerebral ischemia, challenging its direct applicability in current stroke protocols. For peptide users and researchers, this highlights the importance of dose-response optimization and precise timing in neuroprotective strategies. While the observed non-significant directional reductions hint at potential biological activity, a usable protocol for TRH in acute ischemia is far from established. Future research should explore higher doses, different administration routes, or combination therapies to unlock any latent therapeutic potential, as the current findings do not support immediate clinical translation.
trh
thyrotropin-releasing-hormone
cerebral-ischemia
stroke
neuroprotection
inflammation